• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.33% Nasdaq Up0.14%

    Vertex Pharmaceuticals Incorporated (VRTX)

    -NasdaqGS
    121.11 Up 2.21(1.86%) 10:02AM EST - Nasdaq Real Time Price
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
    Total Revenue 1,211,975   1,527,042   1,410,626  
    Cost of Revenue130,277  279,885  80,505  
    Gross Profit 1,081,698   1,247,157   1,330,121  
    Operating Expenses
    Research Development918,783  806,185  707,706  
    Selling General and Administrative362,342  436,796  400,721  
    Non Recurring704,021  1,844  107,874  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (903,448) 2,332   113,820  
    Income from Continuing Operations
    Total Other Income/Expenses Net(49,939)309  (15,694)
    Earnings Before Interest And Taxes(953,387)2,641  98,126  
    Interest Expense22,730  15,022  37,681  
    Income Before Tax(976,117)(12,381)60,445  
    Income Tax Expense(288,567)38,754  19,266  
    Minority Interest242,522  (55,897)(11,605)
    Net Income From Continuing Ops(445,028)(107,032)29,574  
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (445,028) (107,032) 29,574  
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (445,028) (107,032) 29,574  

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.